← Leaderboards
Baldassarre Stea
Nuvox Pharma, Llc
$1,246,286
Attributed
$2,492,571
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2017–23$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$2,492,571 · 1
By mechanism
R44$2,492,571 · 1
Top collaborators
- Evan Charles Unger3 shared
Others in their field
Other Emerging Leaders on “Follow-Up”
- Leonard Freedman · Leidos Biomedical Research, Inc.$102,794,932
- Beth Baseler · Leidos Biomedical Research, Inc.$48,446,535
- Lynn Briscoe · Leidos Biomedical Research, Inc.$41,716,051
- Dale Sandler · Social And Scientific Systems, Inc.$41,380,317
- Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
- Paula Gonzalez-Maya · Fundacion Inciensa$37,578,679
Research focus
Follow-UpFree Radical OxygenExhalationFluorocarbonsAftercareExperimental DesignsAgedArchivesAdverse EventAffectBiological MarkersBone MarrowBreathingChemoradiationChemotherapyAnimalsContrast MediaControlled Clinical TrialsDiagnosisArizonaDoseElectrodesEmulsionsFree Radicals
Grant awards (3)
Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma$492,571
R44 · FY2023 · CA
Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma$1,000,000
R44 · FY2022 · CA
Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma$1,000,000
R44 · FY2017 · CA